SNY Stock Recent News
SNY LATEST HEADLINES
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead's investigational cardiometabolic candidates in Greater China. Under the terms, Sanofi will acquire rights to develop and commercialize investigational plozasiran, Arrowhead's first-in-class RNA interference (RNAi) therap.
Sanofi (NASDAQ:SNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care François-Xavier Roger - Executive VP & CFO Houman Ashrafian - Executive VP & Head of Research Development Paul Hudson - CEO & Director Roy Papatheodorou - Executive VP & General Counsel Thomas Triomphe - Executive Vice President of Vaccines Thomas Kudsk Larsen - Head of Investor Relations Conference Call Participants Benjamin Jackson - Jefferies LLC, Research Division David Reed Risinger - Leerink Partners LLC, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
Sanofi SA SNY reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments.